Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
In view of the strong biological rationale of employing PARP inhibition in high grade glioma,
the current study purposes testing of talazoparib in a biomarker-enriched group of glioma.
Carboplatin will be added to sensitize the tumor to PARP inhibition, and low dose radiation
therapy will be applied to increase talazoparib drug penetration through blood-brain barrier.
The goal is to estimate the effect size of such combinational treatment approach in recurrent
high-grade glioma with DNA damage repair deficiency (dDDR)